Bing Lin, Ph.D., CEO
Dr. Bing Lin joined Zensun USA in 2012 as Director of CMC. He has more than 14-year industrial experience in biotechnology and pharmaceutical companies on protein science and CMC. Before joining Zensun USA, he served as Director of Protein Chemistry in Anaphore and leaded a team for protein production, purification, characterization and CMC. Prior to that, he held lead positions in Novartis GNF as Investigator II and in Alexion Pharmaceuticals as Senior Scientist. Dr. Lin earned his Ph.D. from Kansas State University and the Certificate for Regulatory Affairs Essentials from University of California at San Diego. Since October 2016, Dr. Lin began to take the responsibility as CEO of Zensun USA.
Lei Zhang, Ph.D. VP of Global Clinical Development & Operations
Dr. Zhang serves as VP of Global Clinical Development & Operations at Zensun USA overseeing global clinical studies. Dr. Lei Zhang has over 15 years of experience in clinical & medical affairs that span across the medical device, biotechnology, and diagnostic industries. Prior to Zensun, Dr. Zhang held management positions in Clinical & Medical Affairs and R & D at Alere, Cytori Therapeutics, Inovio Biomedical, Halozyme Therapeutics and Genetronics, Inc. Dr. Zhang earned her Ph.D. in Biophysics from Friedrich-Shiller Univ. in Germany.
Robin Allgren, MD Ph.D. CMO (Consultant)
Dr. Allgren received her Ph.D. degree from Stanford University and MBA from Golden Gate University. She has more than 25 years industry experience, spanning biotech, pharma, medical devices and diagnostics. She successfully executed clinical development activities at all stages of development, from preclinical stage through IND filing, NDA filing and approval. She also has very rich experience in pharmacovigilance.